AZAohan Zu

Aohan Zu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aohan Zu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Liangrong Zheng

    Department of Cardiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    2 shared publications
  • Xingang Sun

    Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China

    2 shared publications
  • Biqi Zhang

    Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003 Hangzhou, Zhejiang, China

    1 shared publication
  • Chengui Zhuo

    Department of Cardiology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, People’s Republic of China

    1 shared publication
  • Chenyu Zuo

    Shanghai Centennial Sci Co Ltd, Shanghai 200032, Peoples R China

    1 shared publication
  • Dongchen Zhou

    Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    Radiofrequency ablation using the ThermoCool SmartTouch Catheter guided by ablation index versus antiarrhythmic drugs in atrial fibrillation treatment in China: a cost-consequence analysis

    by Biqi Zhang, Jie Han, Dongchen Zhou, Jiajia Jiang, Jiawei Zhong, Yunlong Lu, Chenyu Zuo, Xingwei Lu, Jianwei Xuan, Aohan Zu, et al.

    Aim: To evaluate the costs and consequences of two front-line atrial fibrillation (AF) treatments from Chinese healthcare system perspective: radiofrequency catheter ablation (RFCA) using ThermoCool SmartTouch Catheter guided by Ablation Index (STAI), in comparison to antiarrhythmic drugs (AADs). Patients & methods: We simulated clinical and economic consequences for AF patients initially receiving STAI or AADs using a short-term decision tree model leading to a 10-year long-term Markov model. The model projected both clinical consequences and costs associated with, among others, AF, heart failure (HF), strokes, and deaths due to AF or AF related complications. Data informing the models included combination of a local real-world study and published clinical studies. Results: STAI was advantageous versus AADs on all 4 main clinical outcomes evaluated; AF: 25.83% lower (12.84% vs 38.67%), HF: 2.22% lower (1.33% vs 3.55%), stroke or post stroke: 1.82% lower (10.00% vs 11.82%) and deaths due to AF or AF related complications: 0.64% lower (4.11% vs 4.75%). The average total cost per patient in STAI group was yen 16,682 lower ( yen 123,124 vs yen 139,806). The one-way sensitivity analysis indicated that the difference in total cost was most sensitive to annual AF recurrence probability in AADs-treated patients. Probabilistic sensitivity analysis indicated a 98.5% probability that RFCA treatment would result in cost savings by the end of the 10th year. Conclusion: Radiofrequency catheter ablation using SmartTouch catheter guided by Ablation Index was superior to AADs as the first-line AF treatment in Chinese setting with better clinical outcomes and at lower costs over a 10-year time horizon.

  • Open Access

    Cardiac Troponin I and Risk of Stroke: A Mendelian Randomization Study

    by Heng Chen, Xingang Sun, Chengui Zhuo, Jianqiang Zhao, Aohan Zu, Qiqi Wang, Liangrong Zheng

    Purpose: Cardiac troponin I (cTnI) is a well-established biomarker for stroke prediction, especially in patients with heart diseases. However, the causal effect of circulating cTnI on stroke remains unclear. Methods: We employed Mendelian Randomization (MR) analysis to determine the associations between genetically predicted circulating cTnI levels and stroke and its subtypes. Summary-level data for exposure and outcomes were generated from different genome-wide association studies. Single-nucleotide polymorphisms (SNPs) associated with circulating cTnI at genome-wide significance level (P < 5 × 10− 8) were employed as instrumental variables (IVs). We used fixed-effect inverse-variance weighted (IVW) as the main method for pooling MR estimates. Sensitivity analyses and multivariable MR analyses were carried out to assess the robustness of the results. Results: Using the fixed-effects IVW method, we found that genetically elevated plasma cTnI levels may have a causal effect on the risk of cardioembolic stroke (CES) (odds ratio (OR), 1.58; 95% confidence interval (CI), 1.17– 2.13; P = 0.003). Additional analyses including multiplicative random-effects (mre) IVW, weighted median, MR-Egger and MR-PRESSO yielded similar results, but with broader CIs that span 1.0. The total effect of cTnI on CES was attenuated by adjusting for the effect of atrial fibrillation (OR,1.26; 95% CI, 0.76– 2.11; P = 0.371) and smoking (OR,1.53; 95% CI, 0.87– 2.66; P = 0.137). In addition, we found no causal effect of cTnI on the risk of any stroke and other stroke subtypes, including any ischemic stroke, large artery stroke, cardioembolic stroke, small vessel stroke, and intracerebral hemorrhage. These results were consistent across sensitivity analyses. Conclusion: This study provides little evidence that increased serum cTnI levels lead to a higher risk of stroke.